Press Releases Unicycive Therapeutics, Inc.

Equities

UNCY

US90466Y1038

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
1.13 ^USD	+4.63%		+0.89%	+30.23%

Apr. 04	Piper Sandler Initiates Coverage on Unicycive Therapeutics With Overweight Rating, $9 Price Target	MT
Mar. 28	Unicycive Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference	Apr. 10	AQ
Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update	Mar. 28	AQ
Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress	Mar. 25	AQ
Unicycive Announces $50 Million Private Placement	Mar. 14	AQ
Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference	Mar. 13	AQ
Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)	Mar. 07	AQ
Thinking about buying stock in Beyondspring, LAVA Therapeutics, Unicycive Therapeutics, Guardforce AI, or Infobird?	Mar. 06	PR
Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients	Mar. 04	AQ
Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting	Feb. 14	AQ
Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference	Jan. 29	AQ
Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones	Jan. 23	AQ
Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on Dialysis	Dec. 18	AQ
Unicycive Therapeutics to Participate in Two Investor Conferences in December 2023	Nov. 29	AQ
Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update	Nov. 14	AQ
Unicycive Therapeutics Reaches Alignment with the FDA on Path to File New Drug Application for Oxylanthanum Carbonate (OLC)	23-10-23	AQ
Unicycive Therapeutics : October 2023 Corporate Presentation	23-10-04	PU
Unicycive Therapeutics : Failure to Satisfy Listing Rule - Form 8-K	23-09-25	PU
Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD	23-09-06	AQ
Unicycive Therapeutics Featured on Nasdaq Amplify Issuer Spotlight Series	23-08-29	AQ
Unicycive Announces Second Quarter 2023 Financial Results and Provides Business Update	23-08-14	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Unicycive Therapeutics, Inc.

Equities

UNCY

US90466Y1038

Press Releases

Filters